Search Results: 值得信賴的SPLK-1003 新版題庫上線和資格考試中的領先供應商和考試認證Splunk Splunk Enterprise Certified Admin 👄 到▛ www.newdumpspdf.com ▟搜索➽ SPLK-1003 🢪輕鬆取得免費下載最新SPLK-1003題庫
Meet with Christopher Kata, Director of Sales & Marketing on December 13th during the “3rd SoCalBio Digital Health Conference: It Is All About The Analytics” at the Hotel Casa del Mar in San Monica, California. Christopher Kata, Director of Sales & Marketing905 [email protected] 3rd SoCalBio Digital Health Conference: It Is All About The Analytics When:…
Read More
Enable Biosciences Reports Easier and Accurate SARS-CoV-2 Neutralizing Antibody Assay using Dried Blood Spot Samples Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 3, 2022 /PRNewswire/ — Scientists at Enable Biosciences report a novel method to easily, rapidly and accurately detect neutralizing antibodies against SARS-CoV-2 from dried blood spots, named “SONIA” (Split-Oligonucleotide Neighboring…
Read More
Meet with Christopher Kata, Director of Sales & Marketing on March 26th & 27th 2019 at Outsourcing in Clinical Trials South East in North Carolina ! Christopher Kata, Director of Sales & Marketing 905 999-1957 [email protected] When: March 26th & 27th 2019 Where: Sheraton Imperial Hotel and Convention Center, 4700 Emperor Blvd, Durham, NC 27703. Registration:…
Read More
COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in these randomized, double-blind, placebo-controlled Phase 2 trials in the US and UK. COVI-DROPS™ neutralizing antibody was administered as a single low dose intranasal instillation. Results indicate COVI-DROPS is highly active against the original SARS-CoV-2 virus, as well as the variants of concern including highly transmissible and virulent Delta variant…
Read More
Meet with Christopher Kata, Director of Sales & Marketing on June 23rd – 27th 2019 at “DIA 2019” Booth # 2633 in San Deigo CA! Christopher Kata, Director of Sales & Marketing 905 999-1957 [email protected] When: June 23rd – 27th 2019 Where: Booth # 2633 San Deigo Convention Center, 111 W Harbor Drive, San Deigo,…
Read More
Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent Fulgent Genetics’ expertise in high-volume testing powers Epic’s Comprehensive Cancer Profiling Excerpt from the Press Release: SAN DIEGO, Feb. 24, 2022 /PRNewswire/ –Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast…
Read More
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND® Safety Profile Consistent with Label for FDA-approved Indication in Pyruvate Kinase Deficiency – – Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α-…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced two e-poster presentations at the 2021 ASCO Annual Meeting. The presentations include intra-patient dose escalation (IPDE) data from the INVICTUS Phase 3 study of QINLOCK in…
Read More
Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Excerpt from the Press Release: Initial clinical…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Diomics, a San Diego-based biotech company, today announced that it has been awarded a $2,125,000 Medical Technology Enterprise Consortium (MTEC) Other Transaction Agreement (OTA) with the U.S. Department of Defense to accelerate development and testing of its Diocheck™ SARS-CoV-2 Visual Immune Response Indicator, a transdermal skin patch that…
Read More